Bambusa Therapeutics (NASDAQ:BBTX) Director Purchases $40,000,000.00 in Stock

Bambusa Therapeutics, Inc. (NASDAQ:BBTX) Director Ra Capital Management, L.P. acquired 2,500,000 shares of Bambusa Therapeutics stock in a transaction that occurred on Monday, November 2nd. The stock was purchased at an average cost of $16.00 per share, with a total value of $40,000,000.00. Following the completion of the purchase, the director owned 5,933,787 shares in the company, valued at $94,940,592. The trade was a 72.81% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, October 30th, Ra Capital Management, L.P. acquired 453,820 shares of Bambusa Therapeutics stock. The stock was purchased at an average price of $14.63 per share, for a total transaction of $6,639,386.60.

Bambusa Therapeutics Price Performance

Shares of BBTX stock opened at $15.85 on Friday. Bambusa Therapeutics, Inc. has a fifty-two week low of $13.60 and a fifty-two week high of $17.42.

About Bambusa Therapeutics

Bambusa Therapeutics, Inc is a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies designed to redefine standards of care in immunology and inflammation and fundamentally improve patient quality of life. Its pipeline includes BBT001, BBT002, BBT003 and BBT004. Bambusa Therapeutics, Inc is based in BOSTON.